痰生物标志物可预测慢阻肺急性加重
基于SPIROMICS多中心研究,对980例受试者痰上清液进行代谢组学检测,发现慢阻肺患者多种通路生物标志物升高并与痰中性粒细胞计数相关。唾液酸和次黄嘌呤与疾病严重程度强相关,其升高与更短的急性加重时间和改善的预测模型相关。
要点
- 慢阻肺患者痰中唾液酸和次黄嘌呤升高与疾病严重程度强相关。
- 唾液酸和次黄嘌呤升高与更短的急性加重时间相关。
- 在预测模型中加入痰可溶性相生物标志物可改善对未来急性加重的预测。
核心结论
- 痰生物标志物评估提示黏液水化、腺苷代谢、甲硫氨酸 salvage 和氧化应激通路参与慢阻肺气道病理生理特征。
- 靶向这些通路的治疗可能对慢阻肺有益。
- 简单模型加入痰可溶性相生物标志物可改善肺急性加重的预测。
研究设计与样本
- 研究应用质谱代谢组学生物标志物面板检测来自多中心SPIROMICS研究的痰标本。
- 共分析980例患者的痰上清液:77例健康不吸烟者、341例肺功能保留的吸烟者和562例慢阻肺患者。
- 慢阻肺患者中178例为GOLD 1期、303例为GOLD 2期、81例为GOLD 3期。
主要发现
- 慢阻肺患者中多种通路的生物标志物升高,并与痰中性粒细胞计数相关。
- 最显著的分析物(错误发现率0.1)包括唾液酸、次黄嘌呤、黄嘌呤、甲硫腺苷、腺嘌呤和谷胱甘肽。
- 唾液酸和次黄嘌呤与疾病严重程度指标强相关。
- 这些生物标志物升高与更短的急性加重时间和改善的未来急性加重预测模型相关。
临床怎么用
- 可考虑检测痰中唾液酸和次黄嘌呤等生物标志物以评估慢阻肺疾病严重程度和急性加重风险。
- 在预测模型中加入痰可溶性相生物标志物可能改善对未来急性加重的预测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Improved understanding of the pathways associated with airway pathophysiologic features in COPD will identify new predictive biomarkers and novel therapeutic targets. RESEARCH QUESTION: Which physiologic pathways are altered in the airways of patients with COPD and will predict exacerbations? STUDY DESIGN AND METHODS: We applied a mass spectrometric panel of metabolomic biomarkers related to mucus hydration and inflammation to sputa from the multicenter Subpopulations and Intermediate Outcome Measures in COPD Study. Biomarkers elevated in sputa from patients with COPD were evaluated for relationships to measures of COPD disease severity and their ability to predict future exacerbations. RESULTS: Sputum supernatants from 980 patients were analyzed: 77 healthy nonsmokers, 341 smokers with preserved spirometry, and 562 patients with COPD (178 with Global Initiative on Chronic Obstructive Lung Disease [GOLD] stage 1 disease, 303 with GOLD stage 2 disease, and 81 with GOLD stage 3 disease) were analyzed. Biomarkers from multiple pathways were elevated in COPD and correlated with sputum neutrophil counts. Among the most significant analytes (false discovery rate, 0.1) were sialic acid, hypoxanthine, xanthine, methylthioadenosine, adenine, and glutathione. Sialic acid and hypoxanthine were associated strongly with measures of disease severity, and elevation of these biomarkers was associated with shorter time to exacerbation and improved prediction models of future exacerbations. INTERPRETATION: Biomarker evaluation implicated pathways involved in mucus hydration, adenosine metabolism, methionine salvage, and oxidative stress in COPD airway pathophysiologic characteristics. Therapies that target these pathways may be of benefit in COPD, and a simple model adding sputum-soluble phase biomarkers improves prediction of pulmonary exacerbations. TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01969344; URL: www. CLINICALTRIALS: gov.
引用
- Esther, O'Neal, Anderson, et al. Identification of Sputum Biomarkers Predictive of Pulmonary Exacerbations in COPD. Chest. 2021. PMID: 34801592. doi:10.1016/j.chest.2021.10.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。